On Friday, U.S. Silica Holdings Inc (NYSE:SLCA)’s shares declined -1.17% to $36.34, after U.S. Silica Holdings Inc (SLCA), declared that it will release its first quarter 2015 financial results after the New York Stock Exchange closes on Tuesday, April 28, 2015. This release will be followed by a conference call for investors on Wednesday, April 29, 2015 at 9:00 a.m. Eastern Time to talk about the results. Hosting the call will be Bryan Shinn, president and chief executive officer and Don Merril, vice president and chief financial officer.
U.S. Silica Holdings, Inc. produces and sells commercial silica in the United States. It operates through two segments, Oil & Gas Proppants, and Industrial & Specialty Products. The corporation offers whole grain commercial silica products to be used as fracturing sand in connection with oil and natural gas recovery, in addition to sells its whole grain silica products in various size distributions, grain shapes, and chemical purity levels for manufacturing glass products.
Helmerich & Payne, Inc (NYSE:HP)’s shares dropped -1.15% to $73.08, during the last trading session on Friday, as In conjunction with Helmerich & Payne, Inc.’s (HP) second quarter earnings release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, April 23, 2015, at 11:00 a.m. (ET) with John Lindsay, President and CEO, and Juan Pablo Tardio, Vice President and CFO.
Helmerich & Payne, Inc. primarily operates as a contract drilling corporation in South America, the Middle East, and Africa. It provides drilling rigs, equipment, personnel, and camps on a contract basis to explore for and develop oil and gas from onshore areas and fixed platforms, tension-leg platforms, and spars in offshore areas. As of November 13, 2014, the corporations fleet comprised of 333 land rigs in the U.S., 37 international land rigs, and 9 offshore platform rigs. Its contract drilling business operates through three reportable segments: U.S. Land, Offshore, and International Land.
At the end of Friday’s trade, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)‘s shares dipped -1.15% to $66.37 on April 2, Teva Pharmaceutical Industries (TEVA), and Xenon Pharmaceuticals Inc. (Nasdaq:XENE) declared that the first patient has been enrolled into the Phase 2b study designed to evaluate the safety and efficacy of the novel topically applied TV-45070, (4% and 8% w/w ointment) in patients with postherpetic neuralgia (PHN).
TV-45070 is a small molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, counting those that are expressed in the pain-sensing peripheral nervous system. It is being developed for the treatment of patients with various pain indications, counting neuropathic and osteoarthritis pain.
“Postherpetic neuralgia leaves patients with lasting and very painful sensations that seriously influence the ability to function. It is often highly refractory to existing treatments and there is a noteworthy need for new treatment options,” said Dr. Jon Isaacsohn, Teva’s Chief Medical Officer. “The field of pain administration in general is in need of new options. Teva is making advances with a range of innovative new treatments that will hopefully improve the lives of millions of people suffering from pain caused by debilitating conditions such as PHN and osteoarthritis.”
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The corporation operates in two segments, Generic Medicines and Specialty Medicines.
Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL), ended its Friday’s trading session with -1.15% loss, and closed at $2.59, after Gol Linhas Aereas Inteligentes (GOL), declares its 4Q14 Results.
Highlights
- Operating revenue (EBIT) of R$505 million in 2014, with an operating margin of 5.0%, up 89.8% contrast to R$266 million recorded in 2013. In 4Q14, EBIT came to R$170.7 million, a 4.8% improvement over 4Q13, with a margin of 6.3%, up by 0.3 percentage point.
- Net proceed reached R$10 billion in the year, 12.4% more than in 2013, being R$9.0 billion in passenger proceed and R$1 billion in ancillary proceeds, increasing its share of total proceed from 9.3%, in 2013, to 10.1%. International proceed amounted to R$1.2 billion, equivalent to 12% of the total. In 4Q14, net proceed totaled R$2.7 billion, in line with 4Q13.
- EBITDAR came to R$1.813 billion, with a margin of 18.0%, 18.8% up vs. 2013 and the Corporation’s highest ever annual figure. In 4Q14, EBITDAR amounted to R$482.2 million, with a margin of 17.7%.
- The merged load factor raised by 7 percentage points in the year, reaching 76.9%, with the domestic up by 7 percentage points to 77.8%, and international load factors up by 8.3 percentage points to 71%. In 4Q14, the merged load factor was 78.7%, 3.9 percentage points higher than 4Q13.
- Net RASK came to R$20.33 cents in 2014, 12.7% more than 2013 and total CASK wasR$19.31 cents, up by 10,3%. CASK ex-fuel raised by 12.8% for the same period.
- In 2014, GOL obtained neutral operating cash flow and closed the year with a cash position of R$2.5 billion, representing 25% of its last 12 months net proceed.
- The financial leverage ratio (adjusted gross debt/EBITDAR) was 6.7x, as compared to 6.9x at the end of 2013, benefited by improved EBITDAR and partially affected by the 13.4% depreciation of the real.
Gol Linhas Aéreas Inteligentes S.A. provides regular and non-regular air transportation services for passengers, cargoes, and mailbags in Brazil and internationally. It operates in two segments, Flight Transportation and Smiles Loyalty Program. The corporation operates a fleet of 150 aircraft, which comprises 96 aircraft under operating leases and 46 aircraft under finance leases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
